Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLiu Qiang

About this trial

This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.

Eligibility criteria

Qualifiers

Diagnosis of coronary artery disease with prior coronary revascularization (PCI or CABG)

Age ≥ 18 years

Signed informed consent

Disqualifiers

Malignant arrhythmias, severe heart failure, myocardial disease, or structural heart disease

Severe pulmonary insufficiency, severe liver or kidney dysfunction, severe electrolyte disturbances

Pregnancy or breastfeeding

Severe psychiatric disorders, malignant tumors, hematologic diseases, rheumatic immune diseases, or severe infection

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

600 Participants
are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators

Liu Qiang

Lead sponsor

The Third Affiliated hospital of Zhejiang Chinese Medical University

Sponsor institution